Dr. Jonathan W. Riess
Claim this profileUniversity of California Davis Comprehensive Cancer Center
Expert in Skin Cancer
Expert in Cancer
22 reported clinical trials
33 drugs studied
Area of expertise
1Skin Cancer
Global LeaderStage IV
Stage III
PD-L1 positive
2Cancer
Global LeaderStage IV
Stage III
HER2 positive
Affiliated Hospitals
Clinical Trials Jonathan W. Riess is currently running
Osimertinib + Chemotherapy
for Lung Cancer
This study will compare the effectiveness of osimertinib alone with the combination of osimertinib and chemotherapy (carboplatin and pemetrexed) in people with metastatic lung cancer that has a change (mutation) in the gene EGFR. Osimertinib alone is the usual treatment for metastatic EGFR-mutant lung cancer. Researchers think adding chemotherapy to osimertinib could possibly add to the anticancer effects of the usual treatment and help stop cancer from growing or spreading.
Recruiting1 award Phase 29 criteria
Osimertinib + Bevacizumab
for Lung Cancer
This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.
Recruiting2 awards Phase 331 criteria
More about Jonathan W. Riess
Clinical Trial Related5 years of experience running clinical trials · Led 22 trials as a Principal Investigator · 10 Active Clinical TrialsTreatments Jonathan W. Riess has experience with
- Osimertinib
- Carboplatin
- Pembrolizumab
- Cisplatin
- Trastuzumab Deruxtecan
- Cetuximab
Breakdown of trials Jonathan W. Riess has run
Skin Cancer
Cancer
Non-Small Cell Lung Cancer
Squamous Cell Carcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Jonathan W. Riess specialize in?
Jonathan W. Riess focuses on Skin Cancer and Cancer. In particular, much of their work with Skin Cancer has involved Stage IV patients, or patients who are Stage III.
Is Jonathan W. Riess currently recruiting for clinical trials?
Yes, Jonathan W. Riess is currently recruiting for 10 clinical trials in Sacramento California. If you're interested in participating, you should apply.
Are there any treatments that Jonathan W. Riess has studied deeply?
Yes, Jonathan W. Riess has studied treatments such as Osimertinib, Carboplatin, Pembrolizumab.
What is the best way to schedule an appointment with Jonathan W. Riess?
Apply for one of the trials that Jonathan W. Riess is conducting.
What is the office address of Jonathan W. Riess?
The office of Jonathan W. Riess is located at: University of California Davis Comprehensive Cancer Center, Sacramento, California 95817 United States. This is the address for their practice at the University of California Davis Comprehensive Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.